Skip to main content

Table 5 Multivariable Cox regression model, including treatment, VEGF -1498 C/T polymorphism and their interaction as covariates

From: Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

Progression Free Survival
Characteristics N Adjusted HR 95% CI P
Treatment FOLFIRI 107 1   
  FOLFIRI + Beva 111 0.48 0.34-0.73 0.0008
Bevacizumab-Group (N = 111)
-1498 C- 82 1   
  T/T 29 2.97 1.28-6.59 0.011
Control Group (N = 107)
-1498 C- 80 1   
  T/T 27 0.71 0.38-1.27 0.235
Overall Survival
Characteristics N Adjusted HR 95% CI P
Treatment FOLFIRI 107 1   
  FOLFIRI + Beva 111 0.50 0.29-0.94 0.033
Bevacizumab-Group (N = 111)
-1498 C- 82 1   
  T/T 29 2.60 0.89-8.36 0.081
Control Group (N = 107)
-1498 C- 80 1   
  T/T 27 0.66 0.31-1.31 0.239